Metagenomi (MGX) Competitors $1.65 +0.04 (+2.73%) Closing price 03:43 PM EasternExtended Trading$1.66 +0.00 (+0.06%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. MRNA, PRQR, NBTX, YMAB, IMAB, CRDF, INBX, MDWD, SOPH, and MNPRShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Moderna (MRNA), ProQR Therapeutics (PRQR), Nanobiotix (NBTX), Y-mAbs Therapeutics (YMAB), I-Mab (IMAB), Cardiff Oncology (CRDF), Inhibrx Biosciences (INBX), MediWound (MDWD), SOPHiA GENETICS (SOPH), and Monopar Therapeutics (MNPR). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Its Competitors Moderna ProQR Therapeutics Nanobiotix Y-mAbs Therapeutics I-Mab Cardiff Oncology Inhibrx Biosciences MediWound SOPHiA GENETICS Monopar Therapeutics Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Is MRNA or MGX more profitable? Moderna has a net margin of -105.67% compared to Metagenomi's net margin of -172.21%. Moderna's return on equity of -28.69% beat Metagenomi's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-105.67% -28.69% -21.94% Metagenomi -172.21%-31.21%-22.21% Do analysts rate MRNA or MGX? Moderna currently has a consensus target price of $46.61, indicating a potential upside of 52.97%. Metagenomi has a consensus target price of $13.00, indicating a potential upside of 685.97%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts clearly believe Metagenomi is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 15 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04Metagenomi 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in MRNA or MGX? 75.3% of Moderna shares are owned by institutional investors. 11.0% of Moderna shares are owned by insiders. Comparatively, 17.8% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, MRNA or MGX? Moderna has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Metagenomi has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Does the media favor MRNA or MGX? In the previous week, Moderna had 19 more articles in the media than Metagenomi. MarketBeat recorded 19 mentions for Moderna and 0 mentions for Metagenomi. Moderna's average media sentiment score of 0.22 beat Metagenomi's score of 0.00 indicating that Moderna is being referred to more favorably in the media. Company Overall Sentiment Moderna Neutral Metagenomi Neutral Which has better earnings and valuation, MRNA or MGX? Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.24B3.64-$3.56B-$8.73-3.49Metagenomi$52.29M1.18-$78.06M-$2.11-0.78 SummaryModerna beats Metagenomi on 10 of the 17 factors compared between the two stocks. Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$60.18M$2.44B$5.54B$8.95BDividend YieldN/A1.77%5.38%4.08%P/E Ratio-0.788.8627.3820.03Price / Sales1.18680.43422.31120.16Price / CashN/A157.0736.6357.47Price / Book0.264.638.085.67Net Income-$78.06M$31.34M$3.16B$248.47M7 Day Performance4.03%0.84%2.12%2.90%1 Month Performance-6.55%7.92%4.43%5.75%1 Year Performance-57.70%1.87%35.62%21.36% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi1.8108 of 5 stars$1.65+2.7%$13.00+686.0%-61.9%$60.18M$52.29M-0.78236MRNAModerna4.3859 of 5 stars$27.59+1.6%$46.61+68.9%-74.1%$10.50B$3.24B-3.165,800Options VolumePRQRProQR Therapeutics2.1709 of 5 stars$2.04flat$8.00+292.2%+29.5%$214.63M$20.46M-5.83180News CoverageNBTXNanobiotix1.715 of 5 stars$4.73+4.4%$8.00+69.1%-7.1%$213.34M$39.18M0.00100Gap UpYMABY-mAbs Therapeutics2.5717 of 5 stars$4.51-4.0%$15.60+245.9%-62.5%$212.83M$87.68M-7.05150IMABI-Mab3.0867 of 5 stars$2.42-5.8%$6.00+147.9%+44.9%$209.87M$3.89M0.00380News CoverageGap UpCRDFCardiff Oncology1.6637 of 5 stars$3.15flat$9.88+213.5%+72.6%$209.56M$680K-3.4220INBXInhibrx Biosciences1.2592 of 5 stars$14.27-1.1%N/A+16.1%$208.89M$200K0.12166News CoverageMDWDMediWound1.6502 of 5 stars$19.37+0.6%$31.80+64.2%+22.9%$208.16M$20.22M-9.2780News CoverageSOPHSOPHiA GENETICS2.8212 of 5 stars$3.10+0.3%$7.00+125.8%-33.8%$206.06M$65.17M-3.10520Positive NewsMNPRMonopar Therapeutics3.2097 of 5 stars$35.78+6.5%$56.50+57.9%+876.7%$205.47MN/A-10.2810 Related Companies and Tools Related Companies Moderna Competitors ProQR Therapeutics Competitors Nanobiotix Competitors Y-mAbs Therapeutics Competitors I-Mab Competitors Cardiff Oncology Competitors Inhibrx Biosciences Competitors MediWound Competitors SOPHiA GENETICS Competitors Monopar Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
